Security key
10567X101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 36,119
- Total 13F value
- $729,604
- Share change
- +36,119
- SEC-reported price per share
- $20.20
- Number of holders
- 2
- Value change
- +$729,604
- Number of buys
- 2
- Shares outstanding
- 90,186,363
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
2
Top holders
2
BRVE full security history
Ownership snapshot
Full 13F holder table
Braveheart Bio, Inc. SEC filings
Braveheart Bio, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 10567X101
Recent filing periods:
Ownership snapshot
Top reported holders of BRVE - Braveheart Bio, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
3/15
Latest evidence
08 Sep 2026
13D/G
3/4/5
Lead comparable stake: 14%
12 rows are not safely comparable across share classes.
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 3
ORBIMED ADVISORS LLC
14%
AH Bio Fund IV, L.P.
11%
Frazier Life Sciences Public Fund...
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
Director, 10%+ Owner
|
14%
Reported 13D/G
· 08 Sep 2026
|
$335,182,127
12,175,159 shares
|
$0 | 08 Sep 2026 |
| AH Bio Fund IV, L.P. |
3/4/5
13D/G
10%+ Owner
|
11%
Reported 13D/G
· 07 Aug 2026
|
—
10,232,420 shares
|
— | 07 Aug 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.5%
Reported 13D/G
· 07 Aug 2026
|
—
4,976,457 shares
|
$0 | 07 Aug 2026 |
| Forbion Growth III Management B.V. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
21,826,024 shares
|
— | 07 Aug 2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
21,826,024 shares
|
— | 07 Aug 2026 |
| Forbion Ventures Fund VII Cooperatief U.A. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
21,826,024 shares
|
— | 07 Aug 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
36,119
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
0
Q3 2026 holders
2
Holder diff
2
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend